Needham & Company LLC Boosts Sage Therapeutics, Inc. (SAGE) Price Target to $100.00

Sage Therapeutics, Inc. (NASDAQ:SAGE) had its target price boosted by Needham & Company LLC from $86.00 to $100.00 in a research report released on Friday morning, MarketBeat Ratings reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

SAGE has been the subject of a number of other reports. BidaskClub lowered shares of Sage Therapeutics from a buy rating to a hold rating in a report on Wednesday, August 23rd. J P Morgan Chase & Co cut their target price on shares of Sage Therapeutics from $99.00 to $85.00 and set an overweight rating for the company in a report on Tuesday, September 12th. Chardan Capital reissued a hold rating on shares of Sage Therapeutics in a report on Wednesday, September 13th. Cowen and Company reissued a buy rating and issued a $100.00 target price on shares of Sage Therapeutics in a report on Friday, August 4th. Finally, Royal Bank Of Canada reissued a buy rating and issued a $117.00 target price on shares of Sage Therapeutics in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $99.86.

Sage Therapeutics (SAGE) traded up $1.95 during trading on Friday, hitting $97.99. 470,487 shares of the stock traded hands, compared to its average volume of 524,206. Sage Therapeutics has a 52-week low of $44.55 and a 52-week high of $98.80.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.98) by $0.01. The business’s revenue was up .0% on a year-over-year basis. sell-side analysts expect that Sage Therapeutics will post -7.36 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/13/needham-company-llc-boosts-sage-therapeutics-inc-sage-price-target-to-100-00.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its stake in Sage Therapeutics by 1.1% during the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 62 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 138 shares during the period. Keybank National Association OH boosted its stake in Sage Therapeutics by 10.6% during the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Sage Therapeutics by 19.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 497 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in Sage Therapeutics by 0.9% during the second quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock worth $4,723,000 after buying an additional 552 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply